At mechanistic level, have been observed that testosterone exerts a rapid non-genomic effect on skeletal muscle cells similar to that exerted by other steroid hormones such as estrogen, progesterone, vitamin D3, and aldosterone in different cellular types (37). At the cellular level, Sinha-Hikim et al. observed that testosterone induces an increase in cross-sectional area (CSA) in type I and II muscle fibers and in myonuclear quantity, indicating that testosterone exerts more of a hypertrophic than a hyperplasic effect on skeletal muscle (30). Clinically, androgen supplementation has been observed to exert anabolic actions that enhance muscle strength and increase muscle size.
One approach that has drawn recent attention is supplementation with androgens, hormones with anabolic properties whose levels naturally decline with age (9–12). Indeed, most of the intrinsic as well as extrinsic (systemic) muscle changes that occur with age are believed to be involved in the development of sarcopenia (5, 6). This newly identified syndrome impacts both quality and quantity of life for both men and women, often leading to physical disabilities, gait abnormalities, and falls that cause loss of functional independence (4). This review discusses the recent findings regarding sarcopenia, the intrinsic, and extrinsic mechanisms involved in the onset and progression of this disease and the treatment approaches that have been developed based on testosterone deficiency and their implications.
This hypothesis is also supported by the fact that in humans, CD34+ interstitial, mesenchymal cells are AR positive and expression of the AR is androgen dose-dependent (13, 102). Recently, it has been described that satellite cells can be transplanted into the muscle of mice, and they are able to proliferate. However, there are significant controversies regarding both the efficiency and the reality of skeletal muscle differentiation by many of these stem cell types.
So when I start testosterone in my older men, I tell them that that's a real risk that you have to worry about. And again, looking through Mary Shelley's eyes at your work, are there any negative things to this — cardiovascular effects or prostate enlargement in these patients — that might be things we should worry about? But any time that I am replacing a patient with testosterone, I always do a hematocrit before I start, and then I check every 6 months, because that is the biggest limiting factor in the use of testosterone. Any time you use IM injections, it is probably the number one problem that we get with testosterone. We have done that in all of our studies and there is a change. Actually, they have plasma volume contraction, which theoretically increases blood viscosity. As a hematologist, I constantly see men given testosterone as replacement therapy — and as their physicians always say, "But it's just replacement therapy" — who come in with extremely high hematocrits.
In addition for changes at the skeletal muscle level, it has been described that other cell types are involved in testosterone-induced muscle functions. During the differentiation of satellite cells to muscle a normal mitochondrial oxidative metabolism, with low production of ROS, is required to sustain skeletal muscle specification and function. Characteristic features of sarcopenia (diminished muscle mass, force, and power generation) also appear much earlier in MIP knock-out (MIPKO) mice than in their wild-type counterparts. As described by Shen (72) (MIP/MTMR14), a recently described protein, is responsible for sarcopenia pathophysiology by controlling intracellular phosphatidylinositol phosphate (PIP) levels via influencing SOCE and Ca2+ storage and release from the sarcoplasmic reticulum (72). The authors hypothesized that alterations in the turnover rate of certain key Ca2+ handling proteins could account for the functional disturbances observed in skeletal muscle.

Gender: Female

Social links